GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing SL Pharmaceutical Co Ltd (SZSE:002038) » Definitions » Valuation Rank

Beijing SL Pharmaceutical Co (SZSE:002038) Valuation Rank


View and export this data going back to 2004. Start your Free Trial

What is Beijing SL Pharmaceutical Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Beijing SL Pharmaceutical Co Valuation Rank Related Terms

Thank you for viewing the detailed overview of Beijing SL Pharmaceutical Co's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing SL Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.69 Fu shi Road, No.1 Building, Bitongyuan, Haidian district, Beijing, CHN, 100049
Beijing SL Pharmaceutical Co Ltd is a Chinese biotechnology-pharmaceutical company. It is principally focused on developing and marketing gene engineering drugs. The product portfolio of the company includes drugs for Oncology, Hepatopathy and Senile disease. Its products include Filgrastim, Asparaginase, Dasartinib, Enoxaparin, Naftopidil, Ademetionine, Lenalidomide, and others.
Executives
Liang Shu Jie Secretary, Director
Xu Ming Bo Directors, executives
Yang Zhong Fan Supervisors
Chen Yu Lin Director
Qi Yan Ming Supervisors
Xi Wen Ying Executives
Wu Yan Zhuo Executives
Wang Wen Xin Director
Li Ya Jun Executives
Zhao Xia Securities Affairs Representative
Zhang Chun Lei Supervisors
Wang Yong Bo Directors, executives
Lu An Jing Supervisors
Wei Su Yan Director